Global Non-alcoholic Steatohepatitis Market 2023-2027

Global Non-alcoholic Steatohepatitis Market 2023-2027

The non-alcoholic steatohepatitis market is forecasted to grow by USD 11,218.5 mn during 2022-2027, accelerating at a CAGR of 40.05% during the forecast period. The report on the non-alcoholic steatohepatitis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of obesity and metabolic syndrome, rise of global aging population, and advancements in diagnostic technologies.

Technavio's non-alcoholic steatohepatitis market is segmented as below:

By Distribution Channel

• Offline
• Online

By Application

• Diagnosis
• Treatment

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising patient engagement and education as one of the prime reasons driving the non-alcoholic steatohepatitis market growth during the next few years. Also, emergence of combination therapies and integration of digital health solutions will lead to sizable demand in the market.

The report on the non-alcoholic steatohepatitis market covers the following areas:

• Non-alcoholic steatohepatitis market sizing
• Non-alcoholic steatohepatitis market forecast
• Non-alcoholic steatohepatitis market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-alcoholic steatohepatitis market vendors that include AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc., GENFIT SA, Gilead Sciences Inc., GlaxoSmithKline Plc, Inventiva S.A., Madrigal Pharmaceuticals Inc., Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG, Zydus Lifesciences Ltd., and Intercept Pharmaceuticals Inc. Also, the non-alcoholic steatohepatitis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.